Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB1 | P11230 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 6/20 | 0.35 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775792 | 0.89 | CHRNB1 (0.41) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3774126 | 0.87 | CNR2 (0.41) | SLC22A12XDH | |
| SCHEMBL3780627 | 0.86 | CYP11B2 (0.35) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3771516 | 0.86 | NR1H4 (0.36) | LTC4SCYP11B2 | |
| SCHEMBL3780143 | 0.84 | ABL1 (0.34) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3776417 | 0.82 | CHRNB1 (0.41) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3774462 | 0.82 | MAP4K4 (0.41) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3780596 | 0.81 | CTPS1 (0.34) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3778599 | 0.80 | MALT1 (0.38) | LTC4S | |
| SCHEMBL3776533 | 0.80 | MAP4K4 (0.37) | CHRNB4CHRNA3LTC4SFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | CHRNB1 7/4885CHRNB2 18/4885CHRNB4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.